New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer
Abstract
We have developed a novel substance, a polymeric form of fibronectin that we have named sFN, which has profound anti-tumor activities. Importantly, there seems to be no toxicity associated with systemic sFN treatment, even when given over several months. At least two characteristics of sFN contribute to its anti- tumor effects: it is both anti-angiogenic and anti-metastatic. sFN is a complex of fibronectin itself and a fragment from fibronectin, anastellin, which binds tightly to fibronectin and causes polymerization of fibronectin. We have now found that anastellin alone reproduces the anti-angiogenic effects of sFN and that plasma fibronectin is needed for anastellin to work in vivo. This is an important advance in understanding how anastellin (and other anti-angiogenic proteins) function. sFN is particularly effective in suppressing the growth and spreading of experimental ovarian cancer in mice. Anastellin, which would be easier to produce and administer may be a better compound to attempt to advance into clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA406191
Entities
People
- Erkki I. Ruoslahti
Organizations
- Sanford Burnham Prebys Medical Discovery Institute